Why It's Critical To Have A Defined Data Strategy

As the ways in which clinical trials are conducted and monitored continue to modernize at pace, there is an urgent need for digital transformation in the industry. If sponsors are to realize their goals of running flexible, decentralized trials (DCT), risk-based management (RBM), or adaptive trials while adopting big data, artificial intelligence / machine learning (AI/ML), the emphasis must now be on technology solutions that optimize clinical trial data workflows by bringing the technology to the data.

As unprecedented challenges faced the industry in 2020, the world waited on accelerated clinical trials in the rush to find vaccines and therapeutics. This emphasis on speed and progression enabled companies to realize that the current way of conducting clinical trials is neither efficient nor dynamic enough. It has resulted in a crucial shift towards greater digitalization and the adoption of new patient-site centric technologies and processes that focus on continuing patient safety.